Three-month functional prognosis of patients hospitalised due to acute ischaemic stroke in Aragon: regional analysis of the impact of COVID-19.

COVID-19 Cerebral infarction España Ictus isquémico Infarto cerebral Ischaemic stroke Outcomes Pronóstico Spain

Journal

Neurologia
ISSN: 2173-5808
Titre abrégé: Neurologia (Engl Ed)
Pays: Spain
ID NLM: 101778590

Informations de publication

Date de publication:
Sep 2021
Historique:
received: 25 10 2020
accepted: 21 02 2021
pubmed: 9 6 2021
medline: 22 9 2021
entrez: 8 6 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has had an impact on ischaemic stroke management, with a reported decrease in hospital admissions, and even disruptions in healthcare and increased in-hospital mortality. However, there is a lack of evidence on the impact of the pandemic on functional prognosis. The aim of this study is to analyse the effect of the COVID-19 pandemic on the 3-month functional outcomes of patients hospitalised due to acute ischaemic stroke in Aragon (Spain). We reviewed the data of all patients admitted due to ischaemic stroke to any hospital in our regional healthcare system between 30 December 2019 and 3 May 2020. We compared modified Rankin Scale scores and mortality at 3 months in patients hospitalised before and after the declaration of a state of emergency due to the COVID-19 pandemic. In total, 318 patients with acute ischaemic stroke met our inclusion criteria. No differences were observed between periods in global or specific characteristics, with the exception of a higher proportion of patients older than 80 years during the first period (42.2% vs 29.0%, P = .028). In the comparative analysis, we found no significant differences in mortality (12.3 vs 7.9, P = .465) or in the proportion of patients with modified Rankin Scale scores ≤ 2 (57.7% vs 57.1%, P = .425) at 3 months. To our knowledge, this is the first study to analyse the impact of COVID-19 pandemic on the 3-month functional outcomes of patients with ischaemic stroke. In our region, there has been no increase in rates of mortality or disability at 3 months in patients admitted due to ischaemic stroke during the pandemic.

Identifiants

pubmed: 34099423
pii: S2173-5808(21)00078-X
doi: 10.1016/j.nrleng.2021.02.001
pmc: PMC8441252
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

531-536

Informations de copyright

Copyright © 2021 Sociedad Española de Neurología. Published by Elsevier España, S.L.U. All rights reserved.

Auteurs

H Tejada Meza (H)

Sección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain; Unidad de Neurointervencionismo, Servicio de Radiología, Hospital Universitario Miguel Servet, Zaragoza, Spain. Electronic address: htmeza@gmail.com.

Á Lambea Gil (Á)

Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain; Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

C Villar Yus (C)

Sección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.

C Pérez Lázaro (C)

Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.

M P Navarro Pérez (MP)

Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain; Servicio de Neurología, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

I Campello Morer (I)

Servicio de Neurología, Hospital Royo Villanova, Zaragoza, Spain.

Á Giménez Muñoz (Á)

Servicio de Neurología, Hospital Royo Villanova, Zaragoza, Spain.

J Artal Roy (J)

Servicio de Neurología, Hospital San Jorge, Huesca, Spain.

O Alberti González (O)

Servicio de Neurología, Hospital San Jorge, Huesca, Spain.

N Hernando Quintana (N)

Servicio de Neurología, Hospital Obispo Polanco, Teruel, Spain.

P Ruiz Palomino (P)

Servicio de Neurología, Hospital Obispo Polanco, Teruel, Spain.

J A Crespo Burillo (JA)

Servicio de Neurología, Hospital de Barbastro, Huesca, Spain.

C García Arguedas (C)

Servicio de Neurología, Hospital de Barbastro, Huesca, Spain.

L Ballester Marco (L)

Servicio de Neurología, Hospital de Alcañiz, Teruel, Spain.

M Palacin Larroy (M)

Servicio de Neurología, Hospital Ernest Lluch, Zaragoza, Spain.

M Seral Moral (M)

Servicio de Neurología, Hospital Ernest Lluch, Zaragoza, Spain.

J Marta Moreno (J)

Sección de Neurovascular, Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain; Instituto de Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH